Expert Discusses Innovative Add-On Study Design for Ibrutinib as Treatment for Chronic Lymphocytic Leukemia

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the study design could affect future studies.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She discussed the innovative nature of the study design and how this could affect future studies.